$112.1 B

LLY Mkt cap, 16-Aug-2018

Eli Lilly Revenue

Eli Lilly revenue was $21.22 b in FY, 2016 which is a 6.3% year over year increase from the previous period.

Embed Graph

Eli Lilly Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1 b19.6 b20 b21.2 b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b

Gross profit Margin, %

79%75%75%73%

Pre tax profit

5.9 b3 b2.8 b3.4 b

Income tax expense

1.2 b609.8 m381.6 m636.4 m

Net Income

4.7 b2.4 b2.4 b2.7 b

Quarterly

USDQ1, 2018

Revenue

5.7 b

Pre tax profit

1.4 b

Eli Lilly Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m

Inventories

2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b

PP&E

8 b8 b8.1 b8.3 b

Goodwill

1.8 b4 b4 b

Total Assets

35.2 b37.2 b35.6 b38.8 b

Accounts Payable

1.1 b1.1 b1.3 b1.3 b

Dividends Payable

523.5 m530.3 m539 m548.1 m

Current Liabilities

8.9 b11.2 b8.2 b11 b

Long-term debt

4.2 b5.4 b8 b8.4 b

Total Debt

4.2 b5.4 b8 b8.4 b

Common Stock

698.5 m694.6 m691.3 m

Additional Paid-in Capital

5.1 b5.3 b5.6 b5.6 b

Retained Earnings

17 b16.5 b16 b16 b

Total Equity

17.6 b15.4 b14.6 b14.1 b

Debt to Equity Ratio

0.2 x0.3 x0.5 x0.6 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x0.2 x

Financial Leverage

2 x2.4 x2.4 x2.8 x

Quarterly

USDQ1, 2018

Current Liabilities

11.5 b

Additional Paid-in Capital

5.8 b

Eli Lilly Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)

Short-term Borrowings

2.7 b(2.7 b)1.3 b

Long-term Borrowings

(10.5 m)(1 b)(2 b)(200 k)

Dividends Paid

(2.1 b)(2.1 b)(2.1 b)(2.2 b)

Cash From Financing Activities

(3.8 b)(75.1 m)(2.9 b)(559.8 m)

Quarterly

USDQ2, 2018

Depreciation and Amortization

848 m

Cash From Operating Activities

2 b
Report incorrect company information

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Report incorrect company information